Ziihera® (zanidatamab-hrii) Combinations Demonstrate Sustained Survival at Three Years in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma at ESMO 2026

Jazz Pharmaceuticals reported Phase 3 trial results showing Ziihera plus chemotherapy reduced death risk by 24% vs. trastuzumab plus chemo, with 40% survival at three years for Ziihera+tislelizumab+chemo. The data supports FDA-approved first-line use. Investors should monitor adoption, sales, and potential label expansions.

Jazz Pharmaceuticals' Ziihera (zanidatamab) plus chemotherapy showed improved overall survival in HER2+ advanced gastroesophageal adenocarcinoma (GEA) patients. Median OS reached 27.0 months with Ziihera plus tislelizumab and chemotherapy, reducing death risk by 35%. Nearly 40% of patients were alive at three years. Ziihera plus chemotherapy alone also showed a 24% reduction in death risk. The results were presented at a medical conference.

Jazz Pharmaceuticals announced that Samantha Pearce, its Executive Vice President and Chief Commercial Officer, will retire. Her departure is effective upon the appointment of a successor or by June 30, 2027, according to the company. The board will consider both internal and external candidates for the role.

Citigroup initiated coverage on Nuvation Bio (NUVB) and Jazz Pharmaceuticals (JAZZ) with Buy ratings. NUVB received a $12 price target, citing strong sales of Ibtrozi and potential of safusidenib. JAZZ was given a $320 target, highlighting Ziihera's growth potential. Both stocks are seen as covered call opportunities.

Jazz Pharmaceuticals extended and repriced its $1.9B loan, pushing the maturity date to 2033 and reducing the interest rate by 50 basis points. The company borrowed an additional $273.3M to refinance existing debt, with the new tranche amortizing over 25 years.

Jazz Pharmaceuticals presented data at SLEEP 2026 showing Xywav's dosing flexibility for narcolepsy and idiopathic hypersomnia, with stable regimens achievable in ~42 days. Real-world data indicates 91% use twice-nightly regimens, but clinicians often customize doses. Studies also show cardiovascular benefits of low-sodium oxybate. According to Jazz, Xywav's individualized dosing can improve patient outcomes.